# Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease

> **NCT05057273** · PHASE2 · WITHDRAWN · sponsor: **NImmune Biopharma**

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** BT-11
- **DRUG:** Active comparator

## Key facts

- **NCT ID:** NCT05057273
- **Lead sponsor:** NImmune Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-11
- **Primary completion:** 2022-02
- **Final completion:** 2022-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Decision by Landos Biopharma (not related to safety or efficacy)
- **Last updated:** 2023-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05057273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05057273, "Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05057273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*